Equities

Shanghai Henlius Biotech Inc

Shanghai Henlius Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)21.00
  • Today's Change0.00 / 0.00%
  • Shares traded177.80k
  • 1 Year change+37.25%
  • Beta0.7541
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments988841707
Total Receivables, Net865508429
Total Inventory757757420
Prepaid expenses445556
Other current assets, total223135
Total current assets2,6762,1921,647
Property, plant & equipment, net2,6532,2301,667
Goodwill, net------
Intangibles, net4,5114,3323,635
Long term investments------
Note receivable - long term------
Other long term assets16--224
Total assets9,9048,9247,173
LIABILITIES
Accounts payable545714383
Accrued expenses1,059854418
Notes payable/short-term debt000
Current portion long-term debt/capital leases2,8002,5221,571
Other current liabilities, total663912588
Total current liabilities5,0675,0022,960
Total long term debt1,2931,1551,052
Total debt4,0933,6772,623
Deferred income tax------
Minority interest------
Other liabilities, total1,3511,131864
Total liabilities7,7117,2884,876
SHAREHOLDERS EQUITY
Common stock543543543
Additional paid-in capital6,0696,0526,010
Retained earnings (accumulated deficit)(4414)(4952)(4253)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(7)(7.02)(3.02)
Total equity2,1921,6362,297
Total liabilities & shareholders' equity9,9048,9247,173
Total common shares outstanding543543543
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.